aTyr Pharma Announces Second Quarter 2019 Results and Provides Corporate Update
14 août 2019 08h00 HE
|
aTyr Pharma, Inc.
aTyr to report interim safety results from Phase 1b/2a proof-of-concept trial of ATYR1923 in pulmonary sarcoidosis patients in Q4 2019 Company to host conference call and webcast today, August...
aTyr Pharma to Announce Second Quarter 2019 Results on August 14th
07 août 2019 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
Leading Immunobiology Researcher Dr. David Briscoe Joins aTyr Pharma as Scientific Advisor
06 août 2019 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Aug. 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines, today announced the...
aTyr Pharma to Host Key Opinion Leader Call and Webcast on Sarcoidosis and the Current Treatment Landscape
10 juil. 2019 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, July 10, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Strengthens Board of Directors with the Appointment of Two New Members
01 juil. 2019 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, July 01, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces First Quarter 2019 Results and Provides Corporate Update
13 mai 2019 16h05 HE
|
aTyr Pharma, Inc.
Phase 1b/2a proof-of-concept clinical trial of ATYR1923 in pulmonary sarcoidosis patients ongoing Advanced lead position in Neuropilin-2 (NRP-2) biology with inaugural NRP-2 summit Company to host...
aTyr Pharma to Announce First Quarter 2019 Results on May 13th
06 mai 2019 16h58 HE
|
aTyr Pharma, Inc.
SAN DIEGO, May 06, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology
16 avr. 2019 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, April 16, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma Announces $5 Million Registered Direct Offering led by The Federated Kaufmann Small Cap Fund
11 avr. 2019 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, April 11, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...
aTyr Pharma to Present Poster at the American Thoracic Society 2019 International Conference
08 avr. 2019 16h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, April 08, 2019 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel...